Selective D-1 dopamine receptor agonist effects in hyperkinetic extrapyramidal disorders.
The motor and cognitive effects of a selective D-1 dopamine receptor agonist, SKF 39393, were assessed in patients with Huntington's disease, Gilles de la Tourette's syndrome, tardive dyskinesia, and torsion dystonia, using a double-blind placebo-controlled design. Over daily doses ranging from 3.2 to 32 mg/kg and treatment intervals extending from one to seven weeks, no consistent changes could be discerned. The contribution of D-1 receptor mediated mechanisms to the pathophysiology of hyperkinetic extrapyramidal disorders remains uncertain.
Braun
A
A
Experimental Therapeutics Branch, National Institute of Neurological and Communicative Disorders and Stroke, Bethesda, MD 20892.
Mouradian
M M
MM
Mohr
E
E
Fabbrini
G
G
Chase
T N
TN
D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; D000328:Adult; D000368:Aged; D001480:Basal Ganglia Diseases / Q000188:drug therapy*; D001552:Benzazepines / Q000627:therapeutic use*; D015259:Dopamine Agents / Q000627:therapeutic use*; D004311:Double-Blind Method; D004341:Drug Evaluation; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy; D005260:Female; D006801:Humans; D006816:Huntington Disease / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D005879:Tourette Syndrome / Q000188:drug therapy
D001552:Benzazepines; D015259:Dopamine Agents; D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine